C4 Therapeutics GAAP EPS of -$0.44 misses by $0.03, revenue of $11.23M beats by $4.95M

* C4 Therapeutics press release [https://seekingalpha.com/pr/20296363-c4-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business-highlights] (CCCC [https://seekingalpha.com/symbol/CCCC]): Q3 GAAP EPS of -$0.44 misses by $0.03.
* Revenue of $11.23M (-26.9% Y/Y) beats by $4.95M.

MORE ON C4 THERAPEUTICS

* C4 Therapeutics, Inc. (CCCC) Presents at IMS Annual Meeting 2025 Oral Presentation - Slideshow [https://seekingalpha.com/article/4825653-c4-therapeutics-inc-cccc-presents-at-ims-annual-meeting-2025-oral-presentation-slideshow]
* C4 Therapeutics, Inc. (CCCC) Special Call - Slideshow [https://seekingalpha.com/article/4824959-c4-therapeutics-inc-cccc-special-call-slideshow]
* C4 Therapeutics, Inc. (CCCC) Discusses On Phase 1 Trial Data Of Cemsidomide In Multiple Myeloma Presented At IMS 2025 Transcript [https://seekingalpha.com/article/4824706-c4-therapeutics-inc-cccc-discusses-on-phase-1-trial-data-of-cemsidomide-in-multiple-myeloma-presented-at-ims-2025-transcript]
* C4 Therapeutics prices $125M equity offering with warrants [https://seekingalpha.com/news/4504726-c4-therapeutics-prices-125m-equity-offering-with-warrants]
* Seeking Alpha’s Quant Rating on C4 Therapeutics [https://seekingalpha.com/symbol/CCCC/ratings/quant-ratings]